StockData
HUTCHMED (China) Ltd logo

HUTCHMED (China) Ltd (HCM) company profile

HCMNasdaqPharmaceutical PreparationsAlso trades as HMDCF
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 20-F on Mar 5, 2026Score 5/30
$14.40−0.33 (-2.24%)

Close on Nov 17, 2026Market cap $2.51BP/E 5.5Yield –

About HUTCHMED (China)

Pharmaceutical Preparations, SIC 2834

HUTCHMED (China) Limited is a commercial-stage biopharmaceutical company engaged in discovering, developing, and commercializing targeted therapies and immunotherapies. Its research and clinical development pipeline targets patients with various cancers and immunological diseases. The enterprise operates across novel oncology and immunology therapies alongside another venture focused on the marketing and distribution of prescription drugs and healthcare products. Key approved treatments include fruquintinib, savolitinib, and surufatinib, alongside licensed therapies like tazemetostat. The company distributes its medicines directly and collaborates with global pharmaceutical partners to deliver therapies to patients worldwide.

The enterprise maintains global drug development operations and clinical trials, with commercial authorization for its treatments spanning dozens of countries, including China, the United States, Japan, and several European nations. It operates three drug product manufacturing sites situated in Suzhou, Shanghai, and Switzerland, supported by research teams and a domestic oncology commercial sales force. Corporate headquarters are located in Hong Kong, with an additional registered corporate office in the Cayman Islands.

Summary of the business section of HUTCHMED (China)'s latest annual report, written by StockData.

Company profile

Company

Legal name
HUTCHMED (China) Ltd
Founded
2000
Headquarters
Hong Kong, Hong Kong
Address
48th Floor, Cheung Kong Center, 2 Queen'S Road Central
Phone
852-2121-3888
Employees
109, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
E9
Auditor
PricewaterhouseCoopers Zhong Tian LLP, Shenzhen, the Peoples Republic of China

Stock & identifiers

Ticker
HCM
Other tickers
HMDCF
Exchange
Nasdaq
IPO date
Mar 18, 2016
Shares outstanding
872M, Dec 31, 2025
Filer category
Large accelerated filer
Stock splits
10-for-1, May 30, 2019
SEC CIK
1648257
CUSIP
44842L103
ISIN
US44842L1035
FIGI
BBG00B6VCGJ1
Share class FIGI
BBG00B6VCGK9
LEI
2138006X34YDQ6OBYE79
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Chig Fung ChengActing CEO and CFO, Director56,693
Wei-guo SuCEO and CSO, Director3,563,905
Charles George Rupert NixonGroup General Counsel41,763
Lorenso ChiuDeputy Chief Financial Officer8,475
Renu BhatiaDirector16,000
Ling YangDirector–
Tak Wai WongDirector–
Daniel Shao Weng TanDirector–
Dan EldarDirector19,000
Chaohong HuDirector–
Edith ShihDirector100,000

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Mar 18, 2016
Offer price
$13.50
Securities offered
7,500,000
Gross proceeds
$101.25M
Exchange
Nasdaq
Lock-up ends (est.)
Sep 14, 2016

“Per ADS Total Public offering price $13.50 $101,250,000 Underwriting discount (1) $0.945 $7,087,500 Proceeds to Hutchison China MediTech Limited before expenses $12.555 $94,162,500 (1) See "Underwriting" for additional information regarding underwriter compensation.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, a total of 109 employees on our Oncology/Immunology research and development team have M.D.”

Corporate history

Events identified from SEC filings

DateEventDetails
Apr 29, 2021Name changeName changed from Hutchison China MediTech Ltd to HUTCHMED (China) Ltd
Mar 18, 2016IPOInitial public offering priced (424B4 prospectus)
Mar 4, 2016ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?